The proposed dosing for ciclesonide HFA nasal aerosol is 74mcg once-daily (37mcg per spray; one-spray per nostril)
Ciclesonide HFA is indicated for the treatment of symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR), in adults and adolescents age 12 and older.
The delivery system for ciclesonide HFA nasal aerosol is a pressurized metered-dose, nasal aerosol formulation designed to dispense a small volume (50 mcL) of the fine, dry mist of ciclesonide to a patient’s nose.
The University of Tennessee Health Sciences Center Pediatrics and Medicine Michael Blaiss said Ciclesonide HFA nasal aerosol has the potential to be a valuable new treatment option for patients who suffer from seasonal and perennial allergies.
"If approved at the proposed dose, this new product could offer symptom relief with a low volume nasal spray," Blaiss said.